Navigation Links
Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
Date:10/28/2009

EXTON, Pa., Oct. 28 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody that targets a tumor-associated antigen over-expressed in many solid tumors.

Under the terms of the agreement, Morphotek has been granted an exclusive worldwide license for the development, manufacture and sale of the antibody. Financial terms were not disclosed. Preclinical studies, conducted by Centocor Ortho Biotech, have shown that the relevant antigen is over-expressed in many solid tumors.

"We are delighted to conclude this license agreement with Centocor Ortho Biotech as we are committed to bringing healthcare solutions to cancer patients, especially for areas of unmet medical need," said Philip Sass, Ph.D., Chief Operating Officer of Morphotek. "Morphotek is well positioned to apply its technologies, knowledge and expertise in monoclonal antibody development for the development and commercialization of this antibody. The preclinical data package for this antibody have shown anti-cancer effects and we look forward to validating these in human trials."

About Morphotek

Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of novel and proprietary technologies. The technologies have been successfully applied to a variety of molecules that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.

Eisai Inc.

Eisai Inc. is a wholly-owned subsidiary of Eisai Corporation of North America. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), the company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully-integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. has several R&D facilities in Massachusetts, New Jersey and North Carolina, as well as manufacturing facilities in Maryland and North Carolina. For more information about Eisai, please visit www.eisai.com.

*On October 1, 2009, Eisai Research Institute of Boston, Inc. (established in 1987) and Eisai Medical Research Inc. (established in 2002) were merged into Eisai Inc.

SOURCE Morphotek(R), Inc.


'/>"/>
SOURCE Morphotek(R), Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors
2. Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
3. Connectyx Announces the MedFlash Personal Health Manager
4. Allegheny Medical Announces Launch of the New AlleghenyMedical.com
5. Zix Corporation Hits High End of Financial Guidance as Company Announces Third Quarter 2009 Financial Results
6. 1-800-Therapist Announces New Executive Team and Tele-Therapy Offering
7. Ziosoft Announces Agreement with Imaging & Medical Information Technology to Distribute Ziosoft's 3D Advanced Visualization Software in Turkey
8. Sorrento Therapeutics Announces the Appointment of Martina Molsbergen as Vice President, Business Development
9. CardioGenics Holdings Inc. Announces Name, Ticker Symbol and CUSIP Number Change
10. Spain-United States Chamber of Commerce Announces 30th Annual Gala Honoring IBT Group at The Biltmore Hotel - November 6
11. Akorn, Inc. Announces Third Quarter 2009 Earnings Release and Conference Call Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the ... and Your Health on Voice of America, declared on her radio program in November ... the fact that when these bullies attack leaders in corporate America, they are trying ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings ... a team of three acupuncturists to help patients realize their family building goals. ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... that can be seen on a type of MRI, according to a study ... disorder of the central nervous system characterized by tremors or trembling and stiffness ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)...  Lannett Company, Inc. (NYSE: LCI ) today announced ... Prescription for Success Healthcare Conference on December 14, 2016 at 9:20 ... York City . In addition, the company will ... 4 th Annual Boston Healthcare Conference taking place on December ... ...
(Date:12/6/2016)... BROOKLYN, N.Y. , Dec. 6, 2016  Licenders is bringing ... . This new location in Park Slope at 203 13 th ... Brooklyn clientele. "Our goal is ... Our treatment plans are designed to get children right back to ... products are 100% all natural and safe for the whole family," ...
(Date:12/6/2016)... Dec. 6, 2016  "Blood Tests replace Surgical ... ....." The Diagnostic, Monitoring and Screening Test ... diagnostics is occurring using in vitro blood testing ... with impressive backing, has announced a single blood ... moving faster than the market. New technology that ...
Breaking Medicine Technology: